肥胖与动脉粥样硬化的研究进展
摘要
总结动脉粥样硬化的研究历史、发病机制、危险因素、防治及肥胖的研究进展,分析肥胖与动脉粥样硬化的关系,以期能够更好地预防及治疗肥胖所致的动脉粥样硬化。
引文
[1]KING V L,HATCH N W,CHAN H W,et al.A murine model of obesity with accelerated atherosclerosis[J].Obesity,2009,18(1):35-41.
[2]Qin W,Liu F,Wan C.A U-shaped association of body mass index and all-cause mortality in heart failure patients:a dose-response meta-analysis of prospective cohort studies[J].Cardiovascular Therapeutics,2017,35(2):1.
[3]ADLER I.Studies in experimental atherosclerosis:apreliminary report[J].Exp Med,1914,20(2):93-107.
[4]ADLER I.Further studies in experimental atherosclerosis[J].Exp Med,1917,26(4):581-602.
[5]张运,陈文强.中国动脉粥样硬化研究的历史回顾和展望[J].中华心血管病杂志,2017,45(8):668-674.
[6]陈国芬,黄文英.动脉粥样硬化发病机理研究[J].中国医学科学院学报,1989,11(4):246-249.
[7]ROSS R.The pathogenesis of atherosclerosis---an update[J].New Engl J Med,1998,314(8):488-500.
[8]JONASSON L,HOLM J,SKALLI O,et al.Regional accumulations of T cells,macrophages,and smooth muscle cells in the human atherosclerotic plaque[J].Arteriosclerosis,Thrombosis,and Vascular Biology,1986,6(2):131-138.
[9]LIU Y C,ZOU X B,CHAI Y F,et al.Macrophage polarization in inflammatory diseases[J].Int J Biol Sci,2014,10(5):520-529.
[10]ZIVOTI′C I,DJURI′C T,STANKOVI′C A.The HACD4 haplotype as a risk factor for atherosclerosis in males[J].Gene,2017,11:35-40.
[11]NILSSON J,FREDRIKSON G N,BJRKBACKA H,et al.Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease[J].J Intern Med,2009,266(3):221-231.
[12]SHAH P K,CHYU K Y,DIMAYUGA P C,et al.Vaccine for atherosclerosis[J].J Am Coll Cardiol,2014,64(25):2779-2791.
[13]SABATINE M S,GIUGLIANO R P,WIVIOTT S D,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.
[14]STEVENS G A,SINGH G M,LU Y,et al.National,regional,and global trends in adult overweight and obesity prevalences[J].Popular Health Metrics,2012,10(1):22.
[15]MOKDAD A H,BOWMAN B A,FORD E S,et al.The continuing epidemics of obesity and diabetes in the United States[J].JAMA,2001,286:1195-1200.
[16]KEANE K N,CALTON E K,CARLESSI R,et al.The bioenergetics of inflammation:insights into obesity and type 2 diabetes[J].Eur J Clin Nutr,2017,71(7):904-912.
[17]CAN U,BUYUKINAN M,YERLIKAYA F H.The investigation of circulating microRNAs associated with lipid metabolism in childhood obesity[J].Pediatric Obesity,2016,11(3):228-234.
[18]LANDSBERG L,ARONNE L J,MA L J B M,et al.Obesity-related hypertension:pathogenesis,cardiovascular risk,and treatment[J].The Journal of Clinical Hypertension,2013,15(1):20.
[19]FLP P,HARANGI M,SERES I,et al.Paraoxonase-1 and adipokines:potential links between obesity and atherosclerosis[J].Chem Biol Interact,2016,259:388-393.
[20]LANGE S,ANHUTH D,HARTMANN C A,et al.An inflammatory link in atherosclerosis and obesity[J].Hmostaseologie,2015,35(3):272-278.
[21]GEERAERTS X,BOLLI E,FENDT S M,et al.Macrophage metabolism as therapeutic target for cancer,atherosclerosis,and obesity[J].Frontier in Immunology,2017,15(8):289.
[22]MATSUDA M,SHIMOMURA I.Increased oxidative stress in obesity:implications for metabolic syndrome,diabetes,hypertension,dyslipidemia,atherosclerosis,and cancer[J].Obes Res Clin Pract,2013,7(5):330-341.
[23]GRUBERG L,WEISSMAN N J,WAKSMAN R,et al.The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention:the obesity paradox?[J].J Am Coll Cardiol,2002,39(4):578-584.
[2]Qin W,Liu F,Wan C.A U-shaped association of body mass index and all-cause mortality in heart failure patients:a dose-response meta-analysis of prospective cohort studies[J].Cardiovascular Therapeutics,2017,35(2):1.
[3]ADLER I.Studies in experimental atherosclerosis:apreliminary report[J].Exp Med,1914,20(2):93-107.
[4]ADLER I.Further studies in experimental atherosclerosis[J].Exp Med,1917,26(4):581-602.
[5]张运,陈文强.中国动脉粥样硬化研究的历史回顾和展望[J].中华心血管病杂志,2017,45(8):668-674.
[6]陈国芬,黄文英.动脉粥样硬化发病机理研究[J].中国医学科学院学报,1989,11(4):246-249.
[7]ROSS R.The pathogenesis of atherosclerosis---an update[J].New Engl J Med,1998,314(8):488-500.
[8]JONASSON L,HOLM J,SKALLI O,et al.Regional accumulations of T cells,macrophages,and smooth muscle cells in the human atherosclerotic plaque[J].Arteriosclerosis,Thrombosis,and Vascular Biology,1986,6(2):131-138.
[9]LIU Y C,ZOU X B,CHAI Y F,et al.Macrophage polarization in inflammatory diseases[J].Int J Biol Sci,2014,10(5):520-529.
[10]ZIVOTI′C I,DJURI′C T,STANKOVI′C A.The HACD4 haplotype as a risk factor for atherosclerosis in males[J].Gene,2017,11:35-40.
[11]NILSSON J,FREDRIKSON G N,BJRKBACKA H,et al.Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease[J].J Intern Med,2009,266(3):221-231.
[12]SHAH P K,CHYU K Y,DIMAYUGA P C,et al.Vaccine for atherosclerosis[J].J Am Coll Cardiol,2014,64(25):2779-2791.
[13]SABATINE M S,GIUGLIANO R P,WIVIOTT S D,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.
[14]STEVENS G A,SINGH G M,LU Y,et al.National,regional,and global trends in adult overweight and obesity prevalences[J].Popular Health Metrics,2012,10(1):22.
[15]MOKDAD A H,BOWMAN B A,FORD E S,et al.The continuing epidemics of obesity and diabetes in the United States[J].JAMA,2001,286:1195-1200.
[16]KEANE K N,CALTON E K,CARLESSI R,et al.The bioenergetics of inflammation:insights into obesity and type 2 diabetes[J].Eur J Clin Nutr,2017,71(7):904-912.
[17]CAN U,BUYUKINAN M,YERLIKAYA F H.The investigation of circulating microRNAs associated with lipid metabolism in childhood obesity[J].Pediatric Obesity,2016,11(3):228-234.
[18]LANDSBERG L,ARONNE L J,MA L J B M,et al.Obesity-related hypertension:pathogenesis,cardiovascular risk,and treatment[J].The Journal of Clinical Hypertension,2013,15(1):20.
[19]FLP P,HARANGI M,SERES I,et al.Paraoxonase-1 and adipokines:potential links between obesity and atherosclerosis[J].Chem Biol Interact,2016,259:388-393.
[20]LANGE S,ANHUTH D,HARTMANN C A,et al.An inflammatory link in atherosclerosis and obesity[J].Hmostaseologie,2015,35(3):272-278.
[21]GEERAERTS X,BOLLI E,FENDT S M,et al.Macrophage metabolism as therapeutic target for cancer,atherosclerosis,and obesity[J].Frontier in Immunology,2017,15(8):289.
[22]MATSUDA M,SHIMOMURA I.Increased oxidative stress in obesity:implications for metabolic syndrome,diabetes,hypertension,dyslipidemia,atherosclerosis,and cancer[J].Obes Res Clin Pract,2013,7(5):330-341.
[23]GRUBERG L,WEISSMAN N J,WAKSMAN R,et al.The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention:the obesity paradox?[J].J Am Coll Cardiol,2002,39(4):578-584.